These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 24014294)
1. TP53 aberrations in chronic lymphocytic leukemia. Trbusek M; Malcikova J Adv Exp Med Biol; 2013; 792():109-31. PubMed ID: 24014294 [TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344 [TBL] [Abstract][Full Text] [Related]
4. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? Tam CS; Stilgenbauer S Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261 [TBL] [Abstract][Full Text] [Related]
6. TP53 mutation and survival in chronic lymphocytic leukemia. Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090 [TBL] [Abstract][Full Text] [Related]
10. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282 [TBL] [Abstract][Full Text] [Related]
11. TP53 dysfunction in CLL: Implications for prognosis and treatment. Te Raa GD; Kater AP Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075 [TBL] [Abstract][Full Text] [Related]
12. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536 [TBL] [Abstract][Full Text] [Related]
14. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Shindiapina P; Brown JR; Danilov AV Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077 [TBL] [Abstract][Full Text] [Related]